By Amber Deter A CureVac IPO is running through investors’ minds. CureVac’s current project is a coronavirus vaccine. So, investors want to know how they can get in on the action.
But there isn’t any CureVac stock yet. The company is still privately held. However, with CureVac’s newest discovery, the biotech firm has great potential for investors. Here’s what we know…
CureVac IPO: The Business
Dr. Ingmar Hoerr founded CureVac in 2000. It’s a leading biotech company based in Tübingen, Germany. The company uses messenger RNA (mRNA) technology. It helps develop cancer therapies and the treatment of rare diseases. CureVac started working on its first mRNA-based …read more
